Recent and upcoming marketing authorizations and label expansions are increasing the therapy options for non-Hodgkin’s lymphoma (NHL). Despite a flourishing treatment armamentarium, tightening healthcare budgets across the EU5 mean payers must make economical reimbursement decisions, and hematologist-oncologists must work carefully within prescribing constraints arising from evolving cost-containment measures. Access & Reimbursement EU5 content examines the market access factors that influence the success of NHL therapies in the EU5 markets. The series is based on primary research with EU5 hematologist-oncologists, as well as country-specific payers. This research explores how payers and physicians interact and how reimbursement dynamics and payer policies influence the prescribing and uptake of specific therapies for chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), mantel cell leukemia (MCL), and diffuse large B-cell leukemia (DLBCL) at the brand level, focusing particularly on the fast-moving treatment paradigm for CLL.